Trial Profile
A Multi-center Phase II Study of CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
- Indications Follicular lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 28 Jul 2023 Status changed from active, no longer recruiting to completed.
- 16 Feb 2023 Results(n=20) assessing safety and efficacy of azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma published in the Blood
- 29 Apr 2022 Planned End Date changed from 30 May 2022 to 1 May 2023.